The effect of the mode of administration on the hypolipidaemic activity of niacin: Continuous gastrointestinal administration of low-dose niacin improves lipid-lowering efficacy in experimentally-induced hyperlipidaemic rats

被引:9
作者
Lomnicky, Y
Friedman, M
Luria, MH
Raz, I
Hoffman, A
机构
[1] Hebrew Univ Jerusalem, Sch Pharm, Dept Pharmaceut, Fac Med, IL-91120 Jerusalem, Israel
[2] Hadassah Univ Hosp, Dept Med, Diabet Unit, IL-91240 Jerusalem, Israel
[3] Hadassah Univ Hosp, Dept Cardiol, IL-91240 Jerusalem, Israel
关键词
D O I
10.1111/j.2042-7158.1998.tb03339.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The effect of different routes and modes of administration of niacin (nicotinic acid) on its hypolipidaemic activity has been evaluated. Our working hypothesis was that the major sites of niacin action are located presystemically (i.e. in the gut wall or the liver, or both) which would make niacin a gastrointestinal drug. For such drugs continuous administration to the gastrointestinal tract is expected to augment their efficacy compared with bolus oral administration or parenteral administration. The hypothesis was examined in two rat models of experimentally induced hyperlipidaemia-Model A, based on a cholesterol-enriched diet, and Model B, in which acute hyperlipidaemia is induced by intraperitoneal administration of triton (225 mg kg(-1)). Continuous administration of niacin into the duodenum at 1.66 mg h(-1) (total dose 40 mg kg(-1) day(-1)) for up to 7 days (Model A) or at 2.22 mg h(-1) over 18 h (Model B) had significantly greater lipid-reducing effects both on total cholesterol and on triglyceride levels (15-25%) and elevation of high-density lipoprotein (HDL) cholesterol levels than did bolus oral, administration of the same dose. Continuous duodenal infusion of niacin also had an even greater lipid-reducing effect than continuous intravenous infusion of the drug at the same rate and dose. The results indicate that the site(s) of action are located presystemically and that continuous duodenal administration of a low dose of niacin (40 mg kg(-1)) has a greater lipid-lowering effect than a higher dose (200 mg kg(-1)) administered by peroral bolus administration. These conclusions were validated by administration of a specially designed niacin sustained-release matrix tablet formulation that was non-invasively administered to hyperlipidaemic rats. The hypolipidaemic activity of the sustained-release tablet was of similar magnitude to that resulting from continuous duodenal administration, thus providing a pharmacodynamic rationale for this mode of administration.
引用
收藏
页码:1233 / 1239
页数:7
相关论文
共 26 条
[1]   INFLUENCE OF NICOTINIC ACID ON SERUM CHOLESTEROL IN MAN [J].
ALTSCHUL, R ;
HOFFER, A ;
STEPHEN, JD .
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 1955, 54 (02) :558-559
[2]   Moderate dose, three-drug therapy with Niacin, Lovastatin, and Colestipol to reduce low-density lipoprotein cholesterol <100 mg/dl in patients with hyperlipidemia and coronary artery disease [J].
Brown, BG ;
Bardsley, J ;
Poulin, D ;
Hillger, LA ;
Dowdy, A ;
Maher, VMG ;
Zhao, XQ ;
Albers, JJ ;
Knopp, RH .
AMERICAN JOURNAL OF CARDIOLOGY, 1997, 80 (02) :111-115
[3]   INFLUENCE OF DRUG FORMULATION ON DRUG CONCENTRATION-EFFECT RELATIONSHIPS [J].
CASTANEDAHERNANDEZ, G ;
CAILLE, G ;
DUSOUICH, P .
CLINICAL PHARMACOKINETICS, 1994, 26 (02) :135-143
[4]   HEPATOTOXICITY ASSOCIATED WITH SUSTAINED-RELEASE NIACIN [J].
DALTON, TA ;
BERRY, RS .
AMERICAN JOURNAL OF MEDICINE, 1992, 93 (01) :102-104
[5]  
DIPALMA JR, 1991, ANNU REV NUTR, V11, P169, DOI 10.1146/annurev.nu.11.070191.001125
[6]   NICOTINIC-ACID FOR THE TREATMENT OF HYPERLIPOPROTEINEMIA [J].
DROOD, JM ;
ZIMETBAUM, PJ ;
FRISHMAN, WH .
JOURNAL OF CLINICAL PHARMACOLOGY, 1991, 31 (07) :641-650
[7]   NIACIN-INDUCED HEPATITIS - A POTENTIAL SIDE-EFFECT WITH LOW-DOSE TIME-RELEASE NIACIN [J].
ETCHASON, JA ;
MILLER, TD ;
SQUIRES, RW ;
ALLISON, TG ;
GAU, GT ;
MARTTILA, JK ;
KOTTKE, BA .
MAYO CLINIC PROCEEDINGS, 1991, 66 (01) :23-28
[8]  
GRUNDY SM, 1981, J LIPID RES, V22, P24
[9]   NIACIN REVISITED - CLINICAL OBSERVATIONS ON AN IMPORTANT BUT UNDERUTILIZED DRUG [J].
HENKIN, Y ;
OBERMAN, A ;
HURST, DC ;
SEGREST, JP .
AMERICAN JOURNAL OF MEDICINE, 1991, 91 (03) :239-246
[10]   NIACIN REVISITED - A RANDOMIZED, CONTROLLED TRIAL OF WAX-MATRIX SUSTAINED-RELEASE NIACIN IN HYPERCHOLESTEROLEMIA [J].
KEENAN, JM ;
FONTAINE, PL ;
WENZ, JB ;
MYERS, S ;
HUANG, ZQ ;
RIPSIN, CM .
ARCHIVES OF INTERNAL MEDICINE, 1991, 151 (07) :1424-1432